Christian T. Ruff MD, MPHDirector, General Cardiology, Cardiovascular Division, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School Senior Investigator, TIMI Study Group, Boston, Massachusetts
Christian T. Ruff, MD, MPH, is currently the Director of General Cardiology in the Cardiovascular Division at Brigham and Women’s Hospital in Boston, MA, Senior Investigator at the TIMI Study Group, and an Associate Professor of Medicine at Harvard Medical School.
Dr. Ruff graduated from Harvard University, earned his medical degree at Johns Hopkins University School of Medicine, and his masters of public health from the Harvard School of Public Health. Dr. Ruff completed his internal medicine residency and cardiovascular medicine fellowship at the Brigham and Women’s Hospital.
Dr. Ruff is a senior investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group and serves the Director of the Genetics Core Laboratory and the Co-Chairman of the Clinical Events Committee. He has led a broad array of projects, ranging from investigator initiated studies of biomarkers and genetic variants to large clinical trials. Dr. Ruff has investigated the efficacy of safety of antithrombotic therapies across the spectrum of cardiovascular disease, with a focus on stroke prevention in atrial fibrillation.
Dr. Ruff has served on international clinical guideline committees and has been invited to give hundreds of lectures nationally and internationally. He has authored many scholarly articles, editorials, reviews, and book chapters that include the New England Journal of Medicine, Lancet, Journal of the American Medical Association, American Journal of Medicine, Circulation, Journal of the American College of Cardiology, and Nature Reviews Cardiology.
Recent Contributions to PracticeUpdate:
- Effect of 15-mg Edoxaban on Clinical Outcomes in Older Patients With Atrial Fibrillation
- Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants
- Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation
- ABC Scores for Assessment of Stroke or Systemic Embolism and Bleeding Risk in Atrial Fibrillation
- Favorable Outcomes Associated With Apixaban Use in End-Stage Kidney Disease Patients With Atrial Fibrillation
- Causes of Death in Anticoagulated Patients With Atrial Fibrillation
- Assessing Bleeding Risk in Atrial Fibrillation Using a Bedside Score
- Variability in Risk Score Doesn't Invalidate the Score